title: The next phase of chemoprevention research.
abstract: Phase 0 clinical trials are meant to explore mechanism of action, pharmacokinetics, pharmacodynamics, or biodistribution of investigational compounds in an efficient manner with relatively few subjects. Phase 0 designs have been applied sparingly in cancer research, but this issue of the journal provides an example of their utility reported by Reid and colleagues (beginning on page 347). Indeed, aspects of the phase 0 design lend themselves well to chemoprevention research, suggesting that this approach will become more common in the near future.
authors.affiliation: Section of Hematology/Oncology, Department of Medicine, University of Chicago MC2115, Chicago, IL 60637, USA.
authors.forename: Ezra E W
authors.initials: EE
authors.lastname: Cohen
authors.forename: Richard L
authors.initials: RL
authors.lastname: Schilsky
mesh_terms: D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D002227:Carbazoles / Q000494:pharmacology; D018890:Chemoprevention; D002986:Clinical Trials as Topic; D017277:Drug Approval / Q000379:methods; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D006801:Humans; D008495:Medical Oncology / Q000639:trends; D009369:Neoplasms / Q000517:prevention & control; D012107:Research Design; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D016588:Anticarcinogenic Agents; D002227:Carbazoles; C523402:SR 13668